News stories about Cynosure (NASDAQ:CYNO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cynosure earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 45.9986221461631 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Cynosure (CYNO) Stock Price” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://theolympiareport.com/2017/08/22/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-cynosure-cyno-stock-price.html.

About Cynosure

Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.

Insider Buying and Selling by Quarter for Cynosure (NASDAQ:CYNO)

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.